Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lenalidomide in conjunction with methotrexate, leucovorin, cytarabine and rituximab for the treatment of relapsed or refractory CD20-positive aggressive lymphomas: an open-label, multicenter phase I/II trial

Next Previous
X
Search
Trial Profile

Lenalidomide in conjunction with methotrexate, leucovorin, cytarabine and rituximab for the treatment of relapsed or refractory CD20-positive aggressive lymphomas: an open-label, multicenter phase I/II trial

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 07 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cytarabine (Primary) ; Folinic acid (Primary) ; Lenalidomide (Primary) ; Methotrexate (Primary) ; Rituximab (Primary)
  • Indications B-cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms LeMLAR

    • Most Recent Events

    • 25 Feb 2020 Status changed from active, no longer recruiting to completed.
    • 28 Sep 2019 Planned End Date changed from 31 Dec 2019 to 31 Mar 2020.
    • 28 Sep 2019 Planned primary completion date changed from 30 Jun 2019 to 31 Dec 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top